Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPEIAL: TS Polymorphism Prediction for Pemetrexed/Cisplatin in Lung Adenocarcinoma
NCT00940069Phase 2Completed
- Sponsor
- Hunan Cancer Hospital
- Start
- Mar 2009
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed in lung adenocarcinoma, sponsored by Hunan Cancer Hospital. Started Mar 2009; status: completed.
02
Drugs
pemetrexed
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT00940069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00940069.